Publication:
Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.

Simple item page
dc.contributor.authorFarkouh, Michael E
dc.contributor.authorStone, Gregg W
dc.contributor.authorLala, Anuradha
dc.contributor.authorBagiella, Emilia
dc.contributor.authorMoreno, Pedro R
dc.contributor.authorNadkarni, Girish N
dc.contributor.authorBen-Yehuda, Ori
dc.contributor.authorGranada, Juan F
dc.contributor.authorDressler, Ovidiu
dc.contributor.authorTinuoye, Elizabeth O
dc.contributor.authorGranada, Carlos
dc.contributor.authorBustamante, Jessica
dc.contributor.authorPeyra, Carlos
dc.contributor.authorGodoy, Lucas C
dc.contributor.authorPalacios, Igor F
dc.contributor.authorFuster, Valentin
dc.contributor.funderNovo Nordisk Foundationes_ES
dc.contributor.funderNovartises_ES
dc.contributor.funderCanadian Institutes of Health Researches_ES
dc.date.accessioned2023-03-23T09:56:21Z
dc.date.available2023-03-23T09:56:21Z
dc.date.issued2022-03-08
dc.description.abstractClinical, laboratory, and autopsy findings support an association between coronavirus disease-2019 (COVID-19) and thromboembolic disease. Acute COVID-19 infection is characterized by mononuclear cell reactivity and pan-endothelialitis, contributing to a high incidence of thrombosis in large and small blood vessels, both arterial and venous. Observational studies and randomized trials have investigated whether full-dose anticoagulation may improve outcomes compared with prophylactic dose heparin. Although no benefit for therapeutic heparin has been found in patients who are critically ill hospitalized with COVID-19, some studies support a possible role for therapeutic anticoagulation in patients not yet requiring intensive care unit support. We summarize the pathology, rationale, and current evidence for use of anticoagulation in patients with COVID-19 and describe the main design elements of the ongoing FREEDOM COVID-19 Anticoagulation trial, in which 3,600 hospitalized patients with COVID-19 not requiring intensive care unit level of care are being randomized to prophylactic-dose enoxaparin vs therapeutic-dose enoxaparin vs therapeutic-dose apixaban. (FREEDOM COVID-19 Anticoagulation Strategy [FREEDOM COVID]; NCT04512079).es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipDr Farkouh has received research grants from Amgen, Novo Nordisk, and Novartis. Dr Stone has received speaker honoraria from Infraredx; has served as a consultant to Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Abiomed, Ancora, Vectorious, Elucid Bio, Occlutech, CorFlow, Apollo Therapeutics, Impulse Dynamics, Cardiomech, Gore, and Amgen; and has equity/ options from Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, and Xenter. Dr Godoy is supported by the Frederick Banting and Charles Best Canada Graduate Scholarship (Doctoral Research Award) from the Canadian Institutes of Health Research. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.es_ES
dc.format.number9es_ES
dc.format.page917es_ES
dc.format.volume79es_ES
dc.identifier.citationJ Am Coll Cardiol. 2022 Mar 8;79(9):917-928es_ES
dc.identifier.doi10.1016/j.jacc.2021.12.023es_ES
dc.identifier.e-issn1558-3597es_ES
dc.identifier.journalJournal of the American College of Cardiologyes_ES
dc.identifier.pubmedID35241226es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/15697
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.publisherversion10.1016/j.jacc.2021.12.023es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Imagen Cardiovascular y Estudios Poblacionaleses_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshAnticoagulantses_ES
dc.subject.meshCOVID-19es_ES
dc.subject.meshCritical Carees_ES
dc.subject.meshEnoxaparines_ES
dc.subject.meshHospitalizationes_ES
dc.subject.meshHumanses_ES
dc.subject.meshPyrazoleses_ES
dc.subject.meshPyridoneses_ES
dc.subject.meshThromboembolismes_ES
dc.subject.meshThrombosises_ES
dc.titleAnticoagulation in Patients With COVID-19: JACC Review Topic of the Week.es_ES
dc.typereviewes_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication558474d4-85be-4127-bda8-59128f707249
relation.isAuthorOfPublication.latestForDiscovery558474d4-85be-4127-bda8-59128f707249

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Anticoagulation in Patients With COVID_19 J Am Coll Cardiol 2022.pdf
Size:
1.28 MB
Format:
Adobe Portable Document Format
Description:
Artículo
Download

Collections

Grupos de investigación